Juan Vera bought stock once, on Mar 16, 2021

Juan F. Vera, M.D., is a corporate insider and physician-scientist who serves as Chief Development Officer and a member of the Board of Directors at Marker Therapeutics, Inc. (MRKR), where he is also a scientific co‑founder of the company’s multi‑antigen T cell therapeutic platform.( Before assuming executive responsibilities at Marker, Dr. Vera built his career at Baylor College of Medicine’s Center for Cell and Gene Therapy, where he has served as an Associate Professor and led work on novel T‑cell therapies and manufacturing processes for clinical applications.( He has played a key role in designing and testing the G‑Rex® cell culture platform to enable large‑scale T‑cell production and has collaborated with biopharmaceutical companies such as Celgene and Bluebird Bio on the development of CAR T‑cell therapies.(

Dr. Vera’s career highlights include co‑founding Marker’s multi‑antigen T‑cell therapeutic platform, extensive contributions in adoptive T‑cell therapy from research to cGMP manufacturing, and receipt of prestigious awards such as the Idea Development Award from the U.S. Department of Defense and a Mentored Research Scholar Award from the American Cancer Society.( He earned his M.D. from Universidad El Bosque in Bogotá, Colombia, followed by postdoctoral training at Baylor College of Medicine’s Center for Cell and Gene Therapy.( In addition to his executive role at Marker Therapeutics, Dr. Vera has held academic and product development positions in the cell therapy field, underscoring his dual expertise in translational research and corporate leadership.(

Written by Perplexity from public sources.